[Effect of Hemoclar on lipid metabolism and the clinical picture of ischemic heart disease].
The article discusses the results of treatment of 38 patients suffering from ischemic heart disease with hemoclar given in a dose of 200 mg for 25-34 days. Ergometry was carried out and the values of lipid metabolism and creatine phosphokinase activity were studied before and after treatment. The drug caused noticeable decrease in the lipid level, mainly in types IIb and IV hyperlipoproteinemia. Medication with hemoclar was attended by a decrease in the frequency and strength of the anginal attacks and by a lesser increase in the activity of creatine phosphokinase during a load. No side-effects were recorded.
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006496:Heparinoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010426:Pentosan Sulfuric Polyester; D011134:Polysaccharides / Q000627:therapeutic use*; D013997:Time Factors; D014990:Xylans / Q000008:administration & dosage / Q000627:therapeutic use*
D006496:Heparinoids; D008055:Lipids; D011134:Polysaccharides; D014990:Xylans; D010426:Pentosan Sulfuric Polyester
Vliianie gemoklara na lipidnyĭ obmen i kliniku ishemicheskoĭ bolezni serdtsa.